Permission to file an NDA can move a stock price Sarepta Therapeutics (Nasdaq:SRPT) is up 62% this morning on news that the FDA is going to allow the company to file a new drug application for a Duchenne Muscular Dystrophy (DMD) treatment...-The Daily Reckoning